Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors

World Journal of Gastroenterology

Volumn 20, Issue 14, 2014, Pages 4017-4024

  Becker, Valentin ^a   Grotz, Stefan ^a   Schlag, Christoph ^a   Nennstiel, Simon ^a   Beitz, Analena ^a   Haller, Bernhard ^b   Schmid, Roland M ^a   Meining, Alexander ^a   Bajbouj, Monther ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Follow up; Gastroesophageal reflux; Gastroesophageal reflux disease; Impedance pH measurement; Non erosive reflux disease; Proton pump inhibitor; Therapy

Indexed keywords

PANTOPRAZOLE; PROTON PUMP INHIBITOR; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG RESPONSE; EPIGASTRIC FULLNESS; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HOARSENESS; HUMAN; IMPEDANCE; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA AND VOMITING; PH MEASUREMENT; PREDICTIVE VALUE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STOMACH PH; SYMPTOM INDEX; AGED; ESOPHAGEAL PH MONITORING; LIFESTYLE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PH; RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ELECTRIC IMPEDANCE; ESOPHAGEAL PH MONITORING; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; HYDROGEN-ION CONCENTRATION; LIFE STYLE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROTON PUMP INHIBITORS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; ROC CURVE; TREATMENT OUTCOME;

EID: 84898481917     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i14.4017     Document Type: Article

References (27)

1. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 1500-1511 [PMID: 11984534 DOI: 10.1053/gast.2002.32978]
2. Dent J. Pathogenesis of gastro-oesophageal reflux disease and novel options for its therapy. Neurogastroenterol Motil 2008; 20 Suppl 1: 91-102 [PMID: 18402646 DOI: 10.1111/ j.1365-2982.2008.01096.x]
3. Pandolfino JE, Kwiatek MA, Kahrilas PJ. The pathophysiologic basis for epidemiologic trends in gastroesophageal reflux disease. Gastroenterol Clin North Am 2008; 37: 827-843, viii [PMID: 19028320]
4. Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol 2009; 44: 518-534 [PMID: 19365600 DOI: 10.1007/s00535-009-0047-5]
5. Fedorak RN, Veldhuyzen van Zanten S, Bridges R. Canadian Digestive Health Foundation Public Impact Series: gastroesophageal reflux disease in Canada: incidence, prevalence, and direct and indirect economic impact. Can J Gastroenterol 2010; 24: 431-434 [PMID: 20652158]
6. Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-1456 [PMID: 9136821 DOI: 10.1016/S0016-5085(97)70025-8]
7. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-1920; quiz 1943 [PMID: 16928254 DOI: 10.1111/j.1572-0241.2006.00630.x]
8. Mearin F, Ponce J, Ponce M, Balboa A, Gónzalez MA, Zapardiel J. Frequency and clinical implications of supraesophageal and dyspeptic symptoms in gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 2012; 24: 665-674 [PMID: 22330237 DOI: 10.1097/MEG.0b013e3283512139]
9. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-1810 [PMID: 9178669 DOI: 10.1053/gast.1997.v112. pm9178669]
10. John M. Eisenberg Center for Clinical Decisions and Communications Science. Managing Chronic Gastroesophageal Reflux Disease. Comparative Effectiveness Review Summary Guides for Clinicians [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 AHRQ Comparative Effectiveness Reviews. 2011 Sep 23
11. Weijenborg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil 2012; 24: 747-757, e350 [PMID: 22309489]
12. Taghavi SA, Ghasedi M, Saberi-Firoozi M, Alizadeh-Naeeni M, Bagheri-Lankarani K, Kaviani MJ, Hamidpour L. Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole. Gut 2005; 54: 1067-1071 [PMID: 15845561 DOI: 10.1136/gut.2004.054981]
13. Kushnir VM, Sayuk GS, Gyawali CP. Abnormal GERD parameters on ambulatory pH monitoring predict therapeutic success in noncardiac chest pain. Am J Gastroenterol 2010; 105: 1032-1038 [PMID: 19920808 DOI: 10.1038/ajg.2009.646]
14. Zerbib F, Roman S, Ropert A, des Varannes SB, Pouderoux P, Chaput U, Mion F, Vérin E, Galmiche JP, Sifrim D. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006; 101: 1956-1963 [PMID: 16848801 DOI: 10.1111/ j.1572-0241.2006.00711.x]
15. Savarino E, Zentilin P, Tutuian R, Pohl D, Gemignani L, Malesci A, Savarino V. Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. J Gastroenterol 2012; 47: 159-168 [PMID: 22038553 DOI: 10.1007/s00535-011-0480-0]
16. Kushnir VM, Sathyamurthy A, Drapekin J, Gaddam S, Sayuk GS, Gyawali CP. Assessment of concordance of symptom reflux association tests in ambulatory pH monitoring. Aliment Pharmacol Ther 2012; Epub ahead of print [PMID: 22428660 DOI: 10.1111/j.1365-2036.2012.05066]
17. Talley NJ, Meineche-Schmidt V, Paré P, Duckworth M, Räisänen P, Pap A, Kordecki H, Schmid V. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12: 1055-1065 [PMID: 9845395 DOI: 10.1046/j.1365-2036.1998.00410.x]
18. Bytzer P, Jones R, Vakil N, Junghard O, Lind T, Wernersson B, Dent J. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012; 10: 1360-1366 [PMID: 22813439 DOI: 10.1016/j.cgh.2012.06.030]
19. Francis DO, Rymer JA, Slaughter JC, Choksi Y, Jiramongkolchai P, Ogbeide E, Tran C, Goutte M, Garrett CG, Hagaman D, Vaezi MF. High economic burden of caring for patients with suspected extraesophageal reflux. Am J Gastroenterol 2013; 108: 905-911 [PMID: 23545710 DOI: 10.1038/ajg.2013.69]
20. Cho YK. How to Interpret Esophageal Impedance pH Monitoring. J Neurogastroenterol Motil 2010; 16: 327-330 [PMID: 20680174 DOI: 10.5056/jnm.2010.16.3.327]
21. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004; 53: 1024-1031 [PMID: 15194656 DOI: 10.1136/ gut.2003.033290]
22. Shay S, Tutuian R, Sifrim D, Vela M, Wise J, Balaji N, Zhang X, Adhami T, Murray J, Peters J, Castell D. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol 2004; 99: 1037-1043 [PMID: 15180722 DOI: 10.1111/j.1572-0241.2004.04172.x]
23. Becker V, Bajbouj M, Waller K, Schmid RM, Meining A. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors - a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Ther 2007; 26: 1355-1360 [PMID: 17900268 DOI: 10.1111/j.1365-2036.2007.03529.x]
24. Naik RD, Vaezi MF. Extra-esophageal manifestations of GERD: who responds to GERD therapy? Curr Gastroenterol Rep 2013; 15: 318 [PMID: 23435747 DOI: 10.1007/s11894-013-0318-4]
25. Mercer CD, Rue C, Hanelin L, Hill LD. Effect of obesity on esophageal transit. Am J Surg 1985; 149: 177-181 [PMID: 3966634 DOI: 10.1016/S0002-9610(85)80029-5]
26. Mercer CD, Wren SF, DaCosta LR, Beck IT. Lower esophageal sphincter pressure and gastroesophageal pressure gradients in excessively obese patients. J Med 1987; 18: 135-146 [PMID: 3480930]
27. Sharma P, Vakil N, Monyak JT, Silberg DG. Obesity does not affect treatment outcomes with proton pump inhibitors. J Clin Gastroenterol 2013; 47: 672-677 [PMID: 23442835]